Intellia Therapeutics secured a $400 million non-dilutive senior secured term loan from OrbiMed. The agreement provides financial flexibility to advance the company's CRISPR-based therapy pipeline.
OrbiMed provided an initial $75 million at the deal's closing. Intellia can access an additional $325 million upon achieving specific milestones.
The funds support the U.S. approval and commercial launch of lonvo-z for hereditary angioedema. Capital will also advance other programs within the company's pipeline.